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Abstract
Bacterial uptake by phagocytic cells is a vital event in the clearance of invading pathogens
such as Streptococcus pneumoniae. A major role of the P-selectin glycoprotein ligand-1
(PSGL-1) on leukocytes against invasive pneumococcal disease is described in this study.
Phagocytosis experiments using different serotypes demonstrated that PSGL-1 is involved
in the recognition, uptake and killing of S. pneumoniae. Co-localization of several clinical
isolates of S. pneumoniae with PSGL-1 was demonstrated, observing a rapid and active
phagocytosis in the presence of PSGL-1. Furthermore, the pneumococcal capsular poly-
saccharide and the main autolysin of the bacterium—the amidase LytA— were identified
as bacterial ligands for PSGL-1. Experimental models of pneumococcal disease including
invasive pneumonia and systemic infection showed that bacterial levels were markedly
increased in the blood of PSGL-1−/−mice. During pneumonia, PSGL-1 controls the severity
of pneumococcal dissemination from the lung to the bloodstream. In systemic infection, a
major role of PSGL-1 in host defense is to clear the bacteria in the systemic circulation con-
trolling bacterial replication. These results confirmed the importance of this receptor in the
recognition and clearance of S. pneumoniae during invasive pneumococcal disease. Histo-
logical and cellular analysis demonstrated that PSGL-1−/−mice have increased levels of T
cells migrating to the lung than the corresponding wild-type mice. In contrast, during sys-
temic infection, PSGL-1−/−mice had increased numbers of neutrophils and macrophages in
blood, but were less effective controlling the infection process due to the lack of this func-
tional receptor. Overall, this study demonstrates that PSGL-1 is a novel receptor for S.
pneumoniae that contributes to protection against invasive pneumococcal disease.
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Author Summary
S. pneumoniae is one of the most important and devastating human pathogens worldwide,
mainly affecting young children, elderly people and immunocompromised patients. In
terms of host immune defense against invasive pneumococcal isolates, professional phago-
cytes require receptor-mediated recognition of certain ligands on the bacterial surface for
the uptake and clearance of the microorganism. In this study, we demonstrate that the P-
selectin glycoprotein ligand-1 (PSGL-1) on leukocytes is involved in the phagocytosis pro-
cess of S. pneumoniae by targeting the capsule and the surface protein LytA as pathogen-
associated molecular patterns. To explore this process in more detail, we have used wild-
type mice and mice deficient in PSGL-1 demonstrating that lack of PSGL-1 is detrimental
for the host by increasing the susceptibility to the infection and the severity of the pneu-
mococcal invasive disease. Overall, these data show the importance of PSGL-1 on leuko-
cytes in host defense against S. pneumoniae and confirm that PSGL-1 plays a critical
protective role against invasive bacterial disease.
Introduction
Streptococcus pneumoniae (pneumococcus) is one of the major causes of invasive disease
accounting for more deaths than any other vaccine-preventable bacterial infection. This micro-
organism colonizes the human nasopharynx, being one of the leading causes of acute otitis
media, community-acquired pneumonia and invasive pneumococcal disease (IPD) including
sepsis and meningitis [1]. The World Health Organization estimates that nearly 14 million epi-
sodes of serious pneumococcal disease occur every year with a critical impact in childhood
population as pneumonia kills more children than AIDS, malaria and measles combined [1, 2].
Resolution of pneumococcal disease is regulated by the efficient recognition and clearance
of the invading pathogen by professional phagocytes [3]. Leukocytes play an important role in
inflammatory and immune responses against bacterial infection and bacterial clearance
depends on the efficacy of different receptors on phagocytic cells to recognize, internalize and
kill the pathogen [4–7]. Phagocytic receptors on the cell surface trigger phagocytosis following
direct recognition of particulate targets. Interaction between selectins and selectin-ligand mole-
cules is essential for the host-pathogen encounter due to its crucial role in leukocyte extravasa-
tion [8]. In this sense, expression of P-selectin and E-selectin by the endothelium provides
protection against invading pathogens such as S. pneumoniae [9, 10]. P-selectin glycoprotein
ligand-1 (PSGL-1) on leukocytes mediates interactions with P-selectin and E-selectin expressed
by endothelial cells [11]. PSGL-1 is a homodimeric mucin-like glycoprotein expressed on the
surface of almost all circulating leukocytes with a great importance in leukocyte adhesion and
transmigration as it is responsible for the initial steps of the extravasation cascade [8, 12]. How-
ever, certain intracellular pathogens have developed sophisticated strategies exploiting specific
receptors for their own benefit to enter eukaryotic cells and replicate intracellularly [13]. This
is the case of the obliged intracellular pathogens Anaplasma phagocytophilum, Ehrlichia sp.,
and enterovirus 71 that get access inside the cell by binding PSGL-1, causing granulocytic ana-
plasmosis/ehrlichiosis and hand-foot-mouth disease respectively [14–16]. However, there is no
experimental evidence indicating that PSGL-1 could act as a receptor on leukocytes participat-
ing in the recognition and clearance of extracellular invading pathogens such as S. pneumoniae.
In this sense, the main goal of this study was to investigate the protective contribution of
PSGL-1 in host defense against IPD.
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Results
PSGL-1 is a functional receptor in neutrophils involved in the phagocytic
process of S. pneumoniae
The plasma membrane of phagocytes expresses an array of receptors that interact with specific
microbial ligands promoting the internalization and clearance of the potential pathogen. To
evaluate the impact of PSGL-1 in pneumococcal phagocytosis, HL-60 cells differentiated to
granulocytes were used as target cells because they express the same phagocytic receptors as
peripheral blood neutrophils including PSGL-1 [14–17] (S1 Fig). To assess the role of PSGL-1
in the phagocytosis of S. pneumoniae, the receptor function was blocked using the specific
monoclonal antibody KPL-1. This is an accepted method to assess the impact of PSGL-1 in
microbial interaction [14–16]. To determine the generic role of PSGL-1 in host defense against
this important pathogen, clinical isolates of S. pneumoniae belonging to different serotypes
were assessed. Phagocytosis was significantly impaired when PSGL-1 was blocked, indicating
that pneumococcal phagocytosis is more efficient when this receptor is fully active (Fig 1A and
1B). The contribution of FCγ-receptors was evaluated indicating that the effect of PSGL-1 in
phagocytosis is independent of FCγ-receptors activity (S1 Fig). In addition, bacterial killing
mediated by PSGL-1 was examined using three different clinical isolates. Our results showed
that pneumococcal survival increased when PSGL-1 in phagocytic cells was blocked, demon-
strating that this receptor is involved in the clearance of S. pneumoniae (Fig 1C). Finally,
phagocytosis experiments using neutrophils obtained from the spleen of wild-type and PSGL-
1–/–mice by cell sorting, confirmed that PSGL-1 is involved in the phagocytosis of S. pneumo-
niae (Fig 1D and 1E).
To further analyze the kinetics of pneumococcal phagocytosis, cells with PSGL-1—either
active or antibody-blocked— were infected with the D39 (serotype 2) strain expressing the
green fluorescent protein (GFP), and the phagocytosis process was monitored using live imag-
ing confocal microscopy (Fig 2A and 2B, S1 and S2 Movies). When PSGL-1 was active, a rapid
and active phagocytosis was observed, with the majority of the cells containing pneumococcal
cells by the end of the process (Fig 2A and S1 Movie). However, when PSGL-1 receptor was
blocked, the recognition and engulfment of S. pneumoniae was impaired, which confirmed the
importance of PSGL-1 in pneumococcal phagocytosis (Fig 2B and S2 Movie). To confirm the
interaction of S. pneumoniae with PSGL-1, fluorescently-labeled pneumococcal isolates of sero-
types 2, 3, 6B, 11A, 23F and 19A were used to observe co-localization with PSGL-1 (Fig 3 and
S2 Fig). Hence, our findings show that PSGL-1 is involved in the recognition and phagocytosis
of a major human pathogen such as S. pneumoniae contributing therefore, to the variety of
receptors on professional phagocytes that are needed to efficiently identify and destroy invad-
ing pathogens [4–6, 18].
Autolysin LytA and pneumococcal capsular polysaccharide are bacterial
ligands recognized by PSGL-1
Phagocytosis requires receptor-mediated recognition of microbial ligands that are usually
expressed in the surface of invading pathogens. These ligands are frequently known as patho-
gen-associated molecular patterns (PAMPS) which are recognized by specific receptors of the
innate immune system [19]. As LytA—the main cell wall hydrolase of S. pneumoniae— is
located on the bacterial surface and it is essential to interact with critical components of the
host immune response including neutrophils and macrophages [20, 21], we explored the possi-
ble interaction of PSGL-1 with LytA. Pneumococcal recognition by PSGL-1 was hindered in
the absence of LytA, suggesting that LytA might be a bacterial ligand for PSGL-1 (Fig 4A and
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Fig 1. PSGL-1 on HL-60 cells andmurine neutrophils is required for phagocytosis of S. pneumoniae. (A) Phagocytosis mediated by PSGL-1 of
FAM-SE-labeled pneumococcal clinical isolates belonging to different serotypes using a flow cytometry assay. HL-60 cells were incubated with an IgG
isotype negative control that does not block PSGL-1 (black bars), whereas cells exposed to the KPL-1 antibody had the PSGL-1 blocked (open bars). (B)
Examples of flow cytometry histograms of pneumococcal binding to cells incubated with KPL-1 (red) or IgG control (green). (C) Bacterial survival indicated as
CFU/ml of recovered bacteria from HL-60 cells previously exposed (open bars) or not (black bars) to KPL-1. (D−E) Phagocytosis of FAM-SE-labeled D39
strain by neutrophils isolated from the spleen of wild-type (black bar and green histogram) or PSGL-1–/–mice (open bar and red histogram). The blue line in
the histogram shows the pattern of non-infected cells. Error bars represent the SDs and asterisks indicate statistical significance after incubation with KPL-1
compared to the exposure to IgG isotype control or between OP using neutrophils from wild-type mice vs those from PSGL-1–/–mice. Error bars represent the
SDs and asterisks indicate statistical significance after incubation with KPL-1 compared to the exposure to IgG isotype control.
doi:10.1371/journal.ppat.1005500.g001
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4B). Direct interaction between purified LytA and PSGL-1 molecules was observed confirming
that this receptor recognizes LytA (Fig 4C). This interaction was dependent on the concentra-
tion of PSGL-1, suggesting that recognition of S. pneumoniae is enhanced when PSGL-1 levels
are increased. Preincubation of HL-60 cells with purified LytA before infection reduced the
phagocytosis in a similar way than KPL-1 antibody, supporting additional evidence that LytA
interacts with PSGL-1 (S3 Fig). To confirm the interaction of LytA and PSGL-1 we included
the non-capsulated strain (M11) and an isogenic lytAmutant strain (Fig 4D). Our results dem-
onstrated that in the absence of LytA, the binding of S. pneumoniae to PSGL-1 is impaired.
Fig 2. PSGL-1 contributes to the uptake of S. pneumoniae. Kinetics of pneumococcal phagocytosis of S.
pneumoniae D39 (serotype 2) strain expressing GFPmediated by PSGL-1. Images are visualized at different
times by live imaging confocal microscopy and environmental control (A) Phagocytosis of D39 strain using
HL-60 cells with the PSGL-1 active. (B) Phagocytosis of D39 strain by HL-60 cells with the PSGL-1 blocked
after incubation with KPL-1.
doi:10.1371/journal.ppat.1005500.g002
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Although the capsular polysaccharide (CPS) is one of the major virulence factors of S. pneumo-
niae, resistance to phagocytosis can vary with the capsular type, which might explain differ-
ences of invasiveness among strains [22, 23]. Capsule recognition by PSGL-1 was investigated
using a non-capsulated strain (M11) and several isogenic transformants of M11 expressing dif-
ferent CPSs (Fig 4E). The absence of CPS caused impaired recognition by PSGL-1, in compari-
son to the corresponding encapsulated transformants, confirming that PSGL-1 recognizes the
pneumococcal CPS (Fig 4E). However, different levels of binding were observed depending on
the CPS with the weakest recognition for the pneumococcal strain expressing serotype 19A
(Fig 4E). Experiments including purified CPS of type 3 and different concentrations of PSGL-1
were included to investigate the binding of PSGL-1 to the pneumococcal capsule (Fig 4F). This
CPS was assessed because is included in the current PCV-13 vaccine and clinical isolates of
serotype 3 are a major cause of IPD [24]. Direct recognition of purified CPS by PSGL-1 was
Fig 3. Recognition of S. pneumoniae by PSGL-1 is a generic event. Co-localization of FAMS-SE-labeled
S. pneumoniae clinical isolates of different serotypes with PSGL-1 in HL-60 cells differentiated to neutrophils.
Cellular DNA was stained with Hoechst whereas PSGL-1 was visualized with mouse anti-human PSGL-1
antibody followed by a goat anti-mouse Texas-Red staining. (DIC, Differential interference contrast).
doi:10.1371/journal.ppat.1005500.g003
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observed showing a concentration-dependent pattern, which confirms that PSGL-1 recognizes
the capsule of S. pneumoniae (Fig 4F).
PSGL-1 on leukocytes controls the severity of pneumococcal infection
The development of IPD depends of the complex interplay of many factors including virulence
determinants of the pathogen and the efficacy of the host immune response to clear the
Fig 4. PSGL-1 recognizes the pneumococcal LytA autolysin and the capsular polysaccharide. (A) ELISA showing binding of different concentrations
of PSGL-1 to S. pneumoniaeD39 (gray circles) and its isogenic lytAmutant (black squares). (B) ELISA showing binding of different concentrations of PSGL-
1 to S. pneumoniae TIGR4 (gray circles) and its isogenic lytAmutant (black squares). (C) ELISA representing binding of 50 μg of purified LytA protein to
different concentrations of PSGL-1. (D) ELISA representing binding of 0.5 μg/ml of PSGL-1 to M11 strain and an isogenic M11 lytAmutant. (E) ELISA
showing binding of different concentrations of PSGL-1 to the unencapsulated M11 strain (open bars) and the corresponding isogenic transformants
expressing CPS of serotypes 3 (gray bars), 6B (striped bars) and 19A (hatched bars). (F) ELISA indicating binding of 50 μg of CPS of serotype 3 (CPS3) to
different concentrations of PSGL-1. Error bars represent the SDs and asterisks indicate significant P-values for comparison of results of S. pneumoniaewild-
type strains versus the corresponding mutants. For the direct recognition between PSGL-1 and LytA or CPS, asterisks indicate statistical significance of
purified LytA protein or CPS3 incubated with PSGL-1 in comparison to the incubation of LytA or CPS3 in the absence of PSGL-1
doi:10.1371/journal.ppat.1005500.g004
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infection process. A failure to efficiently detect and destroy S. pneumoniae in the lower respira-
tory tract or the systemic circulation lead to severe pneumonia or disseminated infection which
are associated to increased mortality rates [3]. Next, the protective role of PSGL-1 against IPD
was investigated using pneumonia and sepsis models of infection (Fig 5). In pneumonia,
bacterial counts were slightly higher in the bronchoalveolar lavage fluid (BALF) and lung of
Fig 5. Contribution of PSGL-1 to host defense against invasive pneumococcal disease. (A) Bacterial
levels recovered at 6 h and 24 h from BALF, lung and blood of PSGL-1−/−mice (open bars) and wild-type
mice (black bars) after pneumonia infection with the pneumococcal D39 strain. (B) Bacterial levels recovered
from blood of PSGL-1−/−mice (open bars) and wild-type mice (black bars) after sepsis caused by D39 strain.
(C) Survival rates of PSGL-1−/−mice (solid line) and wild-type mice (dotted line) after pneumococcal sepsis
produced by D39 S. pneumoniae strain. (D) Bacterial levels recovered from blood of PSGL-1−/−mice (open
bars) and wild-type mice (black bars) after intravenous infection with D39 strain. (E-F) Bacterial counts in
blood and survival of PSGL-1−/−mice (open bars and solid line) and wild-type mice (black bars and dotted
line) infected by the intraperitoneal route (sepsis) with TIGR4 strain. Error bars represent the SDs and
asterisks indicate statistical significance of bacterial levels of PSGL-1−/−mice compared to wild-type mice.
For differences in survival between wild-type mice and PSGL1−/−mice a long-rank test was used (P <0.01 for
D39 strain and P <0.05 for TIGR4 strain).
doi:10.1371/journal.ppat.1005500.g005
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PSGL-1−/−mice, and much higher in the blood of KO mice (Fig 5A). These bacterial levels
were markedly elevated at 24 h in the blood of PSGL-1−/−mice (with the progression of the
infection), confirming that PSGL-1 contributes to control bacterial load by reducing the sever-
ity of pneumococcal dissemination (Fig 5A). In the sepsis model, PSGL-1−/−mice had greater
levels of bacteria in blood (Fig 5B). In addition, lethal infection developed faster in PSGL-1−/−
mice than in wild-type mice indicating that PSGL-1 plays a critical role in host defense against
IPD by controlling bacterial infection in the systemic circulation (Fig 5B and5C). To confirm
this hypothesis and exclude the contribution of cellular migration mediated by PSGL-1, mice
were directly infected by the intravenous route (Fig 5D). Mice lacking PSGL-1 had increased
levels of bacteria in blood than wild-type mice both at 6 and 24 h confirming that a major func-
tion of PSGL-1 in host defense is to clear the bacteria in the bloodstream controlling the dis-
semination (Fig 5D). To extend the importance of PSGL-1 in the clearance of S. pneumoniae
from the systemic infection, a sepsis model was repeated using a lethal dose of a different sero-
type such as TIGR4 strain. Our findings corroborated the results obtained with the D39 strain
demonstrating that lack of PSGL-1 was associated with increased bacterial counts in blood and
a more severe infection compared to wild-type mice (Fig 5E and 5F). Overall, our findings
demonstrate that PSGL-1 plays an important role against IPD.
PSGL-1 contributes to cellular migration and the inflammatory response
The inflammatory response to infection with S. pneumoniae in PSGL-1−/− and wild-type mice
was characterized in BALF and serum. The pattern of the major cytokines associated to infec-
tion was similar in BALF (Fig 6A), although in serum of PSGL-1−/−mice there were significant
increased levels of IL-5, IL-6, and IFN-γ (P<0.05) which is compatible with the higher bacte-
rial levels found in the blood of these mice (Fig 6B).
Neutrophils predominate within cellular infiltrates in pneumococcal pneumonia and the
consequences of the neutrophil influx for the host can be advantageous or detrimental, depend-
ing on the degree of cellular influx and the ability of the pathogen to successfully avoid the
immune response [3]. Leukocyte infiltration into lungs and circulating leukocytes in blood, were
measured by flow cytometry, using wild-type and PSGL-1−/−mice infected with S. pneumoniae
D39 strain (Fig 7A and 7B). In the pneumonia model (intranasal inoculation), the number of
neutrophils and macrophages were similar in the lungs of both types of mice whereas T cell
counts were higher in PSGL-1−/−mice (Fig 7A). In a systemic model of infection (intravenous
inoculation), however, the number of T cells were similar, although the proportion of neutrophils
and macrophages were significantly higher in PSGL-1−/−mice (Fig 7B), which is compatible with
the higher levels of bacteria in the blood of these mice (Fig 5D). Overall, these results indicate
that PSGL-1−/−mice, despite having greater numbers of leukocytes in blood, had an impaired
ability to clear the bacteria from the bloodstream confirming the importance of PSGL-1 in the
recognition and killing of S. pneumoniae in the systemic circulation.
Immunohistochemical characterization of thin sections from lung tissues confirmed that
mice deficient in PSGL-1 had greater infiltration of T cells and neutrophils compared to wild-
type mice, which are consistent with the severity of the infection process developed in PSGL-
1−/−mice (Fig 7C).
LytA is relevant for the interaction with PSGL-1
To demonstrate that pneumococcal LytA is involved in the physiological effects mediated by
PSGL-1, phagocytic assays were performed using HL-60 cells exposed or not to the KPL-1 anti-
body and a pneumococcal strain lacking LytA (Fig 8A and 8B). Hence, our findings confirmed
that phagocytosis of a LytA deficient strain is not dependent on PSGL-1 on HL-60 cells (Fig 8A
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and 8B). To confirm the relevance of LytA in the interaction with PSGL-1, pneumonia and sep-
sis models of infection were repeated in wild-type and PSGL-1−/−mice using a D39 lytA defi-
cient strain (Fig 8C and 8D). In contrast to mice infected with wild-type D39, there were no
differences in lung or BALF CFU between PSGL-1−/− and wild-type mice infected intranasally
with the D39 lytAmutant strain. Similarly, in the sepsis model there were no differences in
recovered D39 lytA deficient strain CFU between PSGL-1−/− and wild-type mice. These results
confirm that the interaction of LytA with PSGL-1 is important for innate immunity against S.
pneumoniae. (Fig 8C and 8D).
Discussion
Neutrophils are key players in the innate and adaptive immune responses to microbial cells,
since they are critical for rapid clearance of invading bacteria [25, 26]. For this process, neutro-
phils must first detect the microorganisms using surface receptors that are essential to engulf
Fig 6. Impact of PSGL-1 deficiency in the inflammatory response after pneumococcal infection.Cytokine levels (pg/ml) in wild-type mice (black bars)
and PSGL-1−/−mice (open bars) at 24 h after intranasal inoculation of S. pneumoniaeD39 strain. (A) Cytokines determined in BALF. (B) Cytokines measured
in sera. Error bars represent the SDs and asterisks indicate statistical significance of cytokine levels of PSGL-1−/−mice compared to wild-type mice.
doi:10.1371/journal.ppat.1005500.g006
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and kill the pathogen [18, 27]. PSGL-1 is a ligand of P-, E- and L-selectins, and is able to medi-
ate the tethering and rolling of circulating leukocytes on the activated endothelium prior to
their extravasation [8, 11, 12]. The role of P, E and L-selectin as well as certain integrins against
pneumococcal infection has been previously characterized [9, 10, 28, 29]. However, the direct
role of PSGL-1 on leukocytes in host defense against S. pneumoniae including its contribution
to the recognition and clearance of this microorganism is unknown. As this bacterium is highly
variable with up to 96 serotypes described so far [30], we included different serotypes of S.
pneumoniae to investigate the role of PSGL-1 in phagocytosis. Hence, our findings showed that
PSGL-1 is involved in the recognition and phagocytosis of a major human pathogen such as S.
pneumoniae contributing therefore to the variety of receptors on professional phagocytes that
are needed to efficiently identify and destroy invading pathogens [4–6, 18]. For the detection of
the pathogen it is necessary the interaction of phagocytic receptors with bacterial ligands that
are usually exposed on the surface of the microorganism [19]. Using LytA-deficient mutants,
we have recently demonstrated that this surface-exposed protein is a major determinant in the
virulence of S. pneumoniae by interacting with essential components of the immune system
including phagocytes [20]. Our results show now that the LytA autolysin is recognized by
PSGL-1 and this effect is dependent on the level of PSGL-1 suggesting that variations in the
expression of PSGL-1 on leukocytes might contribute to the efficiency of this interaction. One
of the major concerns in the outcome of the infection is that pneumococcal disease can be
Fig 7. Contribution of PSGL-1 to cellular migration in lungs and blood of infectedmice with S. pneumoniae. (A) Neutrophils, macrophages, CD4+T
and CD8+T cells in the lungs of wild-type (black bars) or PSGL-1−/−mice (open bars) after pneumonia infection. (B) Proportion of neutrophils, macrophages,
CD4+T and CD8+T cells in the blood of wild-type (black bars) or PSGL-1−/−mice (open bars) after intravenous infection. (C) Representative lung histological
sections from infected mice that show granulocytes infiltrates in PSGL-1−/−mice visualized by Ly6G staining. T cell infiltrates were observed by CD3 staining.
Original magnification × 10. Scale bars represent 200 μm.
doi:10.1371/journal.ppat.1005500.g007
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produced by clinical isolates of a wide variety of polysaccharide capsules, the main virulence
determinant of S. pneumoniae [22, 23]. In this sense, using pneumococcal transformants
expressing the same genetic background but different CPS, we have demonstrated that PSGL-1
recognizes the capsule of S. pneumoniae. This effect was variable depending on the CPS
expressed, with the lowest binding related to the strain expressing serotype 19A. In this sense,
incidence of IPD cases caused by this serotype has dramatically increased in the last few years
and it has been linked to the emergence of vaccine escape variants that arise by switching the
capsular locus from serotype 4 to 19A [31, 32]. These results are important in terms of patho-
genesis because differences in the recognition of pneumococcal CPS by receptors such as
PSGL-1, might explain why certain serotypes of S. pneumoniae are more associated to IPD and
dissemination worldwide than others [31–33].
The repertoire of host receptors involved in the binding, uptake, signaling and response to
invading pathogens is critical for the outcome of the infection. PSGL-1 is the main selectin
receptor involved in neutrophil adhesion and migration [8]. Although the importance of leuko-
cyte extravasation is relevant in pneumococcal infection [9, 10, 29], the contribution of PSGL-1
Fig 8. Lack of LytA counteracts PSGL-1 deficiency. (A) Phagocytosis of FAM-SE-labeled pneumococcal strains (D39, D39 lytA) using HL-60 cells
exposed to IgG isotype control (open bar) or exposed to KPL-1 (striped bar). (B) Example of flow cytometry histograms showing phagocytosis by HL-60 cells
exposed to IgG isotype control (red) or KPL-1 (green). Error bars represent the SDs and asterisks indicate statistical significance after incubation with KPL-1
compared to the exposure to IgG isotype control. **P <0.01 for the comparison between D39 vs D39 lytA in HL-60 cells exposed to KPL-1. (C) Bacterial
levels recovered at 24 h from BALF and lungs of PSGL-1−/− or wild-type mice after pneumonia infection with the pneumococcal D39 lytAmutant. (D).
Bacterial levels recovered at 4 h and 24 h from blood of PSGL-1−/− or wild-type mice after intraperitoneal infection with the pneumococcal D39 lytA strain.
doi:10.1371/journal.ppat.1005500.g008
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to the resolution of IPD was previously unknown. In this study we have used PSGL-1−/−mice to
investigate the in vivo role of this receptor in host defense against pneumococcal infection. Our
findings confirm that PSGL-1 may act as a pathogen-recognition receptor of the immune sys-
tem [34]. In this sense, PSGL-1 acts in host defense controlling bacterial proliferation, dissemi-
nation and tissue injury which are critical aspects of IPD. This is of great relevance from the
respiratory perspective as invasive pneumonia caused by S. pneumoniae is one of the major
causes of mortality in children and adults [1, 3]. Lack of PSGL-1 has been linked to a greater
susceptibility against the intracellular pathogens Salmonella typhimurium or Citrobacter roden-
tium, which is associated with dramatically increased levels of pro-inflammatory cytokines
after intestinal infection [35, 36]. In the case of S. pneumoniae, bacterial recognition by
immune cells generates an array of cytokines which may play a significant role in host defense.
Increase of IL-5, IL-6 and IFN-γ was observed in PSGL-1–/–mice sera. According to our find-
ings, it has been described that increased serum levels of IL-5 and IL-6 were associated with
reduced microbial clearance and higher mortality rates in sepsis [37, 38]. In addition, the
increased levels of IL-12 and IFN-γ in the lungs of wild-type mice might be protective as IFN-γ
is involved in the IL-12 regulation of neutrophil-mediated host defense against pneumococcal
pneumonia [39].
Bacterial infections of the lower respiratory tract are characterized by massive accumulation
of neutrophils in the alveolar spaces [3, 40]. Our results show that similar numbers of neutro-
phils and macrophages were observed in the lungs of PSGL-1−/−mice. Our results might be
unexpected as PSGL-1 is involved in cellular migration of these cells and therefore, increased
numbers should be present in the lungs of wild-type mice [8]. Hence, our findings can be
explained in the context of a bacterial infection as certain pathogens—including S. pneumo-
niae— have the ability to impair neutrophil migration to the site of infection by cleaving
PSGL-1 [41, 42]. Interestingly, this is in line with previous findings confirming that the absence
of endothelial selectins E, L and P is not associated with impairment of leukocyte emigration to
infection sites after pneumococcal disease [10, 43]. In addition, PSGL-1 negatively regulates
CD4+T cell immune responses in vivo which can explain the increased levels of T cells observed
in the lungs of PSGL-1−/− infected mice [44].
Using an intravenous infection model when no collateral migration effects were expected,
higher numbers of neutrophils and macrophages but not T cells, were observed in PSGL-1−/−
mice. This is consistent with previous observations showing that blood of PSGL-1−/−mice con-
tained similar numbers of lymphocytes although they had a significant increase in the propor-
tion of leukocytes, with enhanced levels of granulocytes and monocytes in comparison to wild-
type mice [45]. This is relevant from the phagocytosis perspective as PSGL-1−/−mice, despite
having increased numbers of these phagocytic cells in the bloodstream, were unable to control
bacterial replication in the blood, leading to the rapid development of fatal infection. Overall,
these results confirm that PSGL-1 on leukocytes plays a critical role in host defense against
pneumococcal infection. As a consequence of pathogen-recognition by PSGL-1, S. pneumoniae
is efficiently engulfed and destroyed, reducing bacterial replication and dissemination in the
host, contributing to control the severity of IPD.
Materials and Methods
Ethics statement
All the experiments involving the use of animals have been performed following the guidelines
of the Bioethical and Animal Welfare Committee of Instituto de Salud Carlos III (ISCIII) that
reviewed and approved protocol CBA PA 52-2011-v2, to be performed at the National Centre
for Microbiology of ISCIII. Animals were bred at Universidad Autónoma de Madrid animal
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facility following institutional guidelines for animal use and care. Infection experiments con-
formed to the Spanish government legislation (RD 1201/2005) and European Community reg-
ulations (86/609/EEC).
Bacterial strains and growth conditions
The S. pneumoniae strains used were D39 (NCTC 07466, serotype 2), TIGR4 (ATCC BAA-
334, serotype 4), and clinical isolates of different serotypes obtained from the Spanish Pneumo-
coccal Reference Laboratory; 957/12 (serotype 3), 1515/97 (serotype 6B), 450/12 (serotype
11A), 3347/12 (serotype 19A), 69 (serotype 19F) and 48 (serotype 23F). The non-encapsulated
S. pneumoniae strain M11 and their isogenic transformants expressing CPS of serotypes 3, 6B
and 19A were also included in this study [46]. S. pneumoniae D39 strain expressing the GFP
was constructed by transformation with plasmid pMV158GFP [47] and used for confocal
microscopy experiments. S. pneumoniae strains were cultured on blood agar plates at 37°C in a
5% CO2 atmosphere, or in Todd-Hewitt broth supplemented with 0.5% yeast extract, to an
optical density at 550 nm (OD550) of 0.5, and stored at −70°C in 10% glycerol as single use
aliquots.
Phagocytosis by HL-60 cells and neutrophils isolated from mice
HL-60 cells (CCL-240; ATCC) differentiated to granulocytes were used and the general condi-
tions of the assay were based on those described previously [17, 48]. Briefly, S. pneumoniae
strains were fluorescently labeled by incubation with FAM-SE (Molecular Probes) in 0.1 M
sodium bicarbonate buffer for 1 h at 37°C, washed five times with Hanks balanced salt solution
(HBSS) and stored at −70°C in 10% glycerol as aliquots for further assays. HL-60 cells were
harvested by centrifugation and washed twice with HBSS and once with HBSS in the presence
of calcium and magnesium ions. Infection assays were performed in the absence of serum to
avoid complement-dependent phagocytosis and 105 HL-60 cells were infected with 2×106 col-
ony forming units (CFU) of viable FAM-SE labeled bacteria. To block PSGL-1, HL-60 cells
were incubated for 1 h at room temperature with 25 μg/ml of the KPL-1 antibody (mouse anti-
human PSGL-1; MBL) or IgG isotype control (mouse anti-human IgG; Novus Biologicals) as
previously described [15, 16]. A similar approach was performed using purified LytA. A mini-
mum of 6,000 cells were analyzed using a FACS Calibur flow cytometer (BD Biosciencies).
Using cytochalasin D, an inhibitor of actin polymerization, we have previously shown that the
majority of the effect on the association of fluorescent S. pneumoniae with HL-60 cells is due to
phagocytosis rather than to adhesion of bacteria to the cell surface [49]. Results were expressed
as a fluorescence index defined as the proportion of positive cells for fluorescent bacteria multi-
plied by the geometric mean of fluorescence intensity which correlates with the amount of bac-
teria phagocytosed per cell [48].
Opsonophagocytosis killing assays were performed in the absence of serum using 105 HL-
60 cells with the PSGL-1 receptor either active or blocked as mentioned above and 2.5 × 104
CFU/ml of S. pneumoniae as previously described [50]. Serial dilutions of culture supernatants
were plated on blood agar plates for bacterial counts determination and results were expressed
as bacterial survival after 45 min incubation of the pneumococcal strains with HL-60 cells
expressing (or not) PSGL-1.
Phagocytosis assays were repeated using neutrophils purified from the spleen of wild-type
and PSGL-1−/−mice by FACS using a FACSAria I (BD Biosciences) dispositive with DIVA ver-
sion 6.1 software as previously described [51]. Briefly, single-cell suspensions were prepared in
staining buffer (2% fetal calf serum in PBS), and non-specific binding was blocked with Fc
block (BD Biosciences). Staining was performed using standard protocols with the following
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antibodies diluted 1/200 in staining buffer including propidium iodide (rat anti-mouse
CD11b-allophycocyanin (APC) and rat anti-mouse GR-1-phycoerythrin; Biolegend).
Confocal microscopy
S. pneumoniae strains labeled with FAM-SE were used for immunofluorescence microscopy.
HL-60 cells previously infected as described above were seeded on 12-mm circular coverslips
for immunofluorescence staining. As HL-60 cells are in suspension, cells were cytofuged at 70
× g for 2 min using a Cytospin centrifuge (Thermo Electron, Pittsburgh, PA), as described else-
where [16]. For the detection of PSGL-1 in HL-60 cells differentiated to granulocytes, cells
were fixed with 3% paraformaldehyde (PFA) for 10 min at room temperature and after two
washes with PBS, coverlips were kept in a solution 1 M NH4Cl-PBS solution. Coverslips con-
taining the infected cells were washed twice in PBS containing 0.1% saponin and once in PBS
and incubated for 30 min with the primary antibody. Staining was performed in PBS contain-
ing 10% horse serum, 0.1% saponin and the primary antibody using a mouse anti-human
PSGL-1 monoclonal antibody (KPL-1; MBL) diluted 1/300. Cellular DNA was stained with
Hoechst (Invitrogen) diluted 1/2500. After 30 min incubation with the primary antibody at
room temperature, coverlips were washed twice with PBS-saponin 0.1%, and once with PBS
pH 7.0 before incubation during 30 min at room temperature with a dilution 1/200 of the sec-
ondary antibody (goat anti-mouse Texas Red; Serotec). Finally, coverslips were washed twice
in PBS containing 0.1% saponin, once in PBS, and once in H2O, mounted with Aqua Poly/
Mount (Polysciences), and analyzed with a Leica spectral SP5 confocal microscope using the
Leica software (LAS-AF).
PSGL-1 binding to S. pneumoniae
Binding of PSGL-1 to S. pneumoniae, purified LytA or CPS was analyzed by ELISA as previ-
ously described [20]. Briefly, whole cell ELISA was performed by coating 96-well plates with
200 μl of exponentially growing bacteria and resuspended in PBS to an OD550 of 1.0. Plates
were air dried at room temperature and blocked with 200 μl of PBS-0.5% BSA-NaN3 for 1 h
before 50 μl of different concentrations of PSGL-1 (R&D systems, USA) were added to each
well. After overnight incubation at 4°C, plates were washed 5 times with PBS-Tween 0.1% and
incubated overnight at 4°C with 50 μl of mouse anti-human PSGL-1 (KPL-1; MBL) diluted 1/
4000. After 5 washes with PBS-Tween 0.1%, plates were incubated with goat anti-mouse IgG
HRP (Southern Biotech) for 30 min at room temperature and developed with o-phenylenedia-
mine (Sigma-Aldrich). Plates were measured at OD492 using a microtiter plate reader (Anthos
2020). Direct binding of PSGL-1 to purified LytA protein or type 3 CPS (ATCC 169-X, Merck
Sharp & Dohme) was performed as described above except that the 96-well plates were coated
with 50 μg of purified LytA protein or CPS per well. Purified LytA protein was obtained by
overexpression in Escherichia coli [52].
Experimental models of infection
Wild-type C57BL/6 mice and PSGL-1−/−mice were bred in a conventional animal facility at
the School of Medicine, Universidad Autónoma de Madrid (UAM). PSGL-1−/−mice were
kindly provided by Dr. D Vestweber and Dr. MKWild (Max Plank Institute for Molecular Bio-
medicine, Münster, Germany). Wild-type C57BL/6 mice obtained from the Jackson Laboratory
and PSGL-1−/−mice were backcrossed and the wild-type and PSGL-1−/− littermates obtained
from crosses of the resulting heterozygous mice were used to breed our wild-type and PSGL-
1−/− colonies used in this study. Animal procedures were approved by the Animal Care and
Use Committee of ISCIII. All mice used were 8–16 weeks old, and within each experiment,
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groups of mice were matched for age and sex. Studies investigating pneumococcal sepsis or
pneumonia were performed using groups of at least 5 mice and infected as previously described
[48]. Briefly, for sepsis, mice were challenged with 5 × 106 CFU/ml for D39 strain or 3 × 104
CFU/ml for TIGR4 strain (in a volume of 200 µl) by the intraperitoneal route, whereas for
pneumonia, mice under anesthesia with isofluorane were inoculated intranasally with 50 µl
containing 107 CFU/mouse of D39 strain. For intravenous inoculation, mice were infected
with 2 × 107 CFU/mouse of D39 strain through the tail vein. At 6 h and 24 h after challenge, a
lethal dose of pentobarbital was administered and bacterial counts were determined from sam-
ples recovered from BALF, lung and blood. Experiments were repeated twice using 5 mice in
each group and results were expressed as Log10 CFU/ml of bacteria recovered from the differ-
ent sites. Cytokines were measured from BALF and blood of wild-type mice and PSGL-1−/−
mice infected with D39 strain by the intranasal route as explained above. Cytokines levels (IL-
2, IL-4, IL-5, IL-6, IL-10, IL-12p70, GM-CSF, TNF-α and IFN-γ) were determined by using a
Luminex magnetic bead array assay (Bio-Rad) according to manufacturer protocols.
Experiments investigating cellular populations in lungs and blood after pneumococcal
infection were performed in wild-type and PSGL-1−/−mice infected as explained above using a
FACS assay as previously described [51, 53]. Briefly, single-cell suspensions were prepared in
staining buffer (2% fetal calf serum in PBS), and non-specific binding was blocked with Fc
block (BD Biosciences). Staining was performed using standard protocols with the following
antibodies diluted 1/400 in staining buffer (rat anti-mouse CD11b-allophycocyanin (APC),
Biolegend; rat anti-mouse CD4-FITC, Biolegend; rat anti-mouse CD8-APC, Biolegend; rat
anti-mouse GR-1-phycoerythrin; Biolegend) [51, 53]. Cells were analyzed on a FACSCanto I
using the FlowJo version 6.3.4 software package.
Lung sectioning and histology
Mice were euthanized with pentobarbital and lungs were inflated and fixed with 4% PFA in
PBS. Lungs were paraffin-embedded and 5-μm sections were obtained. Infiltrates of granulo-
cytes and T cells were measured by staining with anti-Ly-6G/6C (antigen retrieval pH 6.5, 1/
400, Abcam ab2557) and anti-CD3 (antigen retrieval pH 6.0, 1/200, Santa Cruz Biotechnology
sc-1127) antibodies respectively. Immunohistochemistry was performed with the Dako LSAB+
System-HRP following manufacturer’s instructions.
Statistical analysis
Data are representative of results obtained from repeated independent experiments, and each
data point represents the mean and standard deviations (SD) for 3 to 5 replicates. Statistical
analysis was performed by using two-tailed Student’s t test (for two groups), whereas analysis
of variance (ANOVA) followed by a Dunnett’s post hoc test was chosen for multiple compari-
sons. Survival was analyzed by the log-rank test. GraphPad InStat version 5.0 (GraphPad Soft-
ware, San Diego, CA) was used for statistical analysis. Differences were considered statistically
significant with P<0.05 () and highly significant with P<0.01 () and P<0.001 ().
Supporting Information
S1 Fig. Expression of receptors on HL-60 cells and impact of FCγ-receptors in the phagocy-
tosis mediated by PSGL-1. (A) Expression of different receptors on HL-60 cells exposed or
not to dimethylformamide (DMF) for granulocytic differentiation. (B) Phagocytosis of
FAM-SE-labeled D39 strain using HL-60 cells exposed to KPL-1 (open bar) or exposed to
KPL-1 and Fcγ-R blocking agent (striped bar) in combination.
(TIF)
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S2 Fig. Co-localization of PSGL-1 and S. pneumoniae. Local co-localization of FAM-SE S.
pneumoniae (green), Cellular DNA (blue) and PSGL-1 (red) is shown and quantified by plot-
ting the fluorescence intensity and the distance (in μm).
(TIF)
S3 Fig. Previous exposure of HL-60 cells to LytA impairs the uptake. (A) Blockage of PSGL-
1-mediated phagocytosis by preincubation with purified LytA. HL-60 cells were incubated for
1 h with 0.1μg/ml or 0.01 μg/ml of purified LytA (open bars) or without LytA (black bar) before
infection with D39 strain. (B) Example of flow cytometry histogram of cells incubated with
(red) or without (green) LytA. Error bars represent the SDs and asterisks indicate statistical sig-
nificance of pneumococcal phagocytosis by HL-60 cells preincubated with purified LytA in
comparison to incubation without LytA.
(TIF)
S1 Movie. Recognition and phagocytosis of S. pneumoniae is enhanced when PSGL-1 is
fully functional.HL-60 cells with the PSGL-1 active were infected for 30 min with the D39
strain expressing GFP and visualized by live imaging confocal microscopy and environmental
control. Bacteria are markedly recognized and trapped by the cells.
(MPG)
S2 Movie. Recognition and phagocytosis of S. pneumoniae is impaired when PSGL-1 is
blocked.HL-60 cells with the PSGL-1 blocked by KPL-1 treatment for 1h were infected for 30
min with the D39 strain expressing GFP and visualized by live imaging confocal microscopy
and environmental control. Bacterial uptake is impaired and S. pneumoniae diverts the phago-
cytosis process very efficiently.
(MPG)
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